Cytokinetics to Announce Second Quarter Results on August 6, 2026

Cytokinetics announced it will report second quarter 2026 results on August 6, 2026, followed by a conference call at 4:30 PM ET. The company highlighted positive topline results from its ACACIA-HCM Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy patients and plans to discuss findings with regulatory authorities.

07/23/2026, 4:00 PM • GlobeNewswire

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Cytokinetics CEO Robert Blum sold 7,500 shares at $82.02 per share after exercising options at $10.60, generating $615,150 in proceeds. The sale represents only 2% of his total equity holdings, with the CEO retaining 381,986 shares and 186,745 options. The transaction appears to be routine diversification following the company's successful MYQORZO drug launch, which generated $4.8 million in first-quarter revenue and has been prescribed to approximately 680 patients by over 275 doctors.

07/14/2026, 5:20 PM • The Motley Fool

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics granted stock options, restricted stock units (RSUs), and performance stock units (PSUs) to 12 newly hired employees as material inducements to employment. The grants include 24,784 stock options at $71.38 per share, 16,429 RSUs vesting over 3 years, and 2,242 PSUs tied to performance goals. The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

06/17/2026, 4:00 PM • GlobeNewswire

Cytokinetics to Participate in June Investor Conferences

Cytokinetics announced that its management team will participate in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. The company will host fireside chats at both events, with live webcasts available on its investor relations website.

05/27/2026, 4:00 PM • GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics granted stock options to purchase 20,807 shares and 13,793 RSUs to 8 newly hired employees on May 15, 2026 as material inducements to employment. The stock options have an exercise price of $75.85 per share and vest over 4 years, while RSUs vest over 3 years. The company is a specialty cardiovascular biopharmaceutical firm with its approved drug MYQORZO® for obstructive hypertrophic cardiomyopathy and several investigational candidates in development.

05/18/2026, 4:00 PM • GlobeNewswire

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company will discuss its cardiovascular biopharmaceutical pipeline, including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and ongoing development of omecamtiv mecarbil and ulacamten for heart failure treatments.

05/12/2026, 4:00 PM • GlobeNewswire

Cytokinetics to Announce First Quarter Results on May 5, 2026

Cytokinetics announced it will report first quarter 2026 results on May 5, 2026, followed by a conference call at 4:30 PM ET. The specialty cardiovascular biopharmaceutical company will discuss financial results and provide business updates on its pipeline including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and investigational drugs omecamtiv mecarbil and ulacamten for various heart failure indications.

04/21/2026, 4:00 PM • GlobeNewswire

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.

03/23/2026, 1:17 PM • The Motley Fool

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics granted stock options to purchase 8,628 shares and 5,719 restricted stock units to 5 new employees hired in February and March 2026 as material inducements to employment. The stock options have an exercise price of $60.06 per share and vest over 4 years, while RSUs vest over 3 years with a 40-40-20 schedule.

03/18/2026, 4:00 PM • GlobeNewswire

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

Cytokinetics executive Andrew Callos exercised and sold 15,000 stock options for approximately $928,950 in early February 2026, weeks after the FDA approval and market launch of the company's first commercial cardiac drug, myqorzo. The transaction reduced his direct holdings by 22.9% to 50,440 shares. The sale comes as Cytokinetics transitions to commercial-stage operations following significant investment in launch readiness.

03/09/2026, 2:18 PM • The Motley Fool

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Cytokinetics announced FDA approval of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy in December 2025, with U.S. commercial launch underway and first prescriptions dispensed. The company also received approvals from China's NMPA and European Commission. Cytokinetics reported $1.22 billion in cash and investments as of December 31, 2025, with 2026 guidance of $830-870 million in combined R&D and SG&A expenses. The company expects to report topline results from ACACIA-HCM in Q2 2026 and launch in Germany in Q2 2026.

02/24/2026, 4:00 PM • GlobeNewswire

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.

02/19/2026, 3:30 AM • GlobeNewswire

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics announced it will report fourth quarter 2025 results on February 24, 2026, followed by a conference call at 4:30 PM ET. The specialty cardiovascular biopharmaceutical company highlighted its approved cardiac myosin inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy, with a European Commission decision expected in Q1 2026. The company is also developing omecamtiv mecarbil and ulacamten for various heart failure indications.

02/12/2026, 4:00 PM • GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics granted stock options to purchase 29,416 shares and 19,825 restricted stock units to 8 employees hired in December 2025 and January 2026 as material inducements to employment. The stock options have an exercise price of $63.44 per share and vest over 4 years, while RSUs vest over 3 years with a 40-40-20 schedule.

01/20/2026, 4:00 PM • GlobeNewswire

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics' CEO Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, a specialty cardiovascular biopharmaceutical firm, has FDA-approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy and is advancing a pipeline of cardiac muscle dysfunction treatments.

01/05/2026, 4:00 PM • GlobeNewswire